

Cezmi A Akdis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1446636/publications.pdf>

Version: 2024-02-01

471
papers

47,783
citations

1163

111
h-index

2375

198
g-index

484
all docs

484
docs citations

484
times ranked

43010
citing authors

#	ARTICLE	IF	CITATIONS
1	COVID-19 vaccinesâ€”The way forward. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 15-16.	2.7	3
2	Environmentâ€dependent alterations of immune mediators in urban and rural South African children with atopic dermatitis. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 569-581.	2.7	14
3	Cutaneous and systemic hyperinflammation drives maculopapular drug exanthema in severely ill COVID-19 patients. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 595-608.	2.7	21
4	Experimental rhinovirus infection induces an antiviral response in circulating B cells which is dysregulated in patients with asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 130-142.	2.7	10
5	EAACI Biologicals Guidelinesâ€”Omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12â€17 years old. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 17-38.	2.7	19
6	Cellular and molecular mechanisms of allergic asthma. Molecular Aspects of Medicine, 2022, 85, 100995.	2.7	71
7	Direct platelet adhesion potentiates group 2 innate lymphoid cell functions. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 843-855.	2.7	7
8	Physical activity in asthma control and its immune modulatory effect in asthmatic preschoolers. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 1216-1230.	2.7	8
9	Climate change: A call to action for the United Nations. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 1087-1090.	2.7	26
10	Cannabinoids induce functional Tregs by promoting tolerogenic DCs via autophagy and metabolic reprogramming. Mucosal Immunology, 2022, 15, 96-108.	2.7	25
11	The cannabinoid WIN55212â€2 suppresses effector Tâ€cell responses and promotes regulatory T cells in human tonsils. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 1029-1032.	2.7	6
12	Increased circulating CRTH2⁺Tregs are associated with asthma control and exacerbation. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 681-685.	2.7	10
13	The effect of allergy and asthma as a comorbidity on the susceptibility and outcomes of COVID-19. International Immunology, 2022, 34, 177-188.	1.8	27
14	The epithelial barrier hypothesis proposes a comprehensive understanding of the origins of allergic and other chronic noncommunicable diseases. Journal of Allergy and Clinical Immunology, 2022, 149, 41-44.	1.5	42
15	T regulatory cells from atopic asthmatic individuals show a Th2â€like phenotype. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 1320-1324.	2.7	10
16	Cannabinoid WIN55212â€2 impairs peanutâ€allergic sensitization and promotes the generation of allergenâ€specific regulatory T cells. Clinical and Experimental Allergy, 2022, 52, 540-549.	1.4	7
17	Climate change and global health: A call to more research and more action. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 1389-1407.	2.7	60
18	Introduction to Mechanisms of Allergic Diseases. , 2022, , 1-24.		1

#	ARTICLE	IF	CITATIONS
19	Is the epithelial barrier hypothesis the key to understanding the higher incidence and excess mortality during COVID-19 pandemic? The case of Northern Italy. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 1408-1417.	2.7	13
20	The past, present, and future of allergic diseases in China. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 354-356.	2.7	3
21	Alpine altitude climate treatment for severe and uncontrolled asthma: An EAACI position paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 1991-2024.	2.7	21
22	Epithelial barrier hypothesis: Effect of the external exposome on the microbiome and epithelial barriers in allergic disease. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 1418-1449.	2.7	132
23	COVID-19 vaccination in patients receiving allergen immunotherapy (AIT) or biologicals: EAACI recommendations. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2313-2336.	2.7	12
24	Effects of non-steroidal anti-inflammatory drugs and other eicosanoid pathway modifiers on antiviral and allergic responses: EAACI task force on eicosanoids consensus report in times of COVID-19. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2337-2354.	2.7	9
25	Involvement and therapeutic implications of airway epithelial barrier dysfunction in type 2 inflammation of asthma. <i>Chinese Medical Journal</i> , 2022, 135, 519-531.	0.9	7
26	Differentiation of bronchial epithelial spheroids in the presence of IL-13 recapitulates characteristic features of asthmatic airway epithelia. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2229-2233.	2.7	10
27	Leukocyte redistribution as immunological biomarker of corticosteroid resistance in severe asthma. <i>Clinical and Experimental Allergy</i> , 2022, 52, 1183-1194.	1.4	5
28	Mesenchymal stromal cells-derived small extracellular vesicles modulate DC function to suppress Th2 responses via IL-10 in patients with allergic rhinitis. <i>European Journal of Immunology</i> , 2022, 52, 1129-1140.	1.6	17
29	Epithelial barrier hypothesis and the development of allergic and autoimmune diseases. <i>Allergo Journal International</i> , 2022, 31, 91-102.	0.9	8
30	Obituary in memory of Giovanni Pajno. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2578-2579.	2.7	0
31	Innate lymphoid cell subsets in obese asthma patients: Difference in activated cells in peripheral blood and their relationship to disease severity. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2835-2839.	2.7	1
32	Desert dust and respiratory diseases: Further insights into the epithelial barrier hypothesis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 3490-3492.	2.7	8
33	Monkeypox outbreak in Europe, UK, North America, and Australia: A changing trend of a zoonotic disease. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2284-2286.	2.7	23
34	Immune-inflammatory proteome of elite ice hockey players before and after SARS-CoV-2 infection. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 3144-3147.	2.7	1
35	Role of dietary fiber in promoting immune health: An EAACI position paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 3185-3198.	2.7	48
36	The cannabinoid WIN55212-2 restores rhinovirus-induced epithelial barrier disruption. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 1900-1902.	2.7	10

#	ARTICLE	IF	CITATIONS
37	Allergic reactions to the first COVID-19 vaccine: A potential role of polyethylene glycol?. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 1617-1618.	2.7	111
38	Current perspective on eicosanoids in asthma and allergic diseases: EAACI Task Force consensus report, part I. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 114-130.	2.7	40
39	Biologicals in atopic disease in pregnancy: An EAACI position paper. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 71-89.	2.7	41
40	EAACI Biologicals Guidelinesâ€”Recommendations for severe asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 14-44.	2.7	156
41	Clinical characteristics of 182 pediatric COVID-19 patients with different severities and allergic status. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 510-532.	2.7	143
42	COVID-19 pandemic: Practical considerations on the organization of an allergy clinicâ€”An EAACI/ARIA Position Paper. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 648-676.	2.7	79
43	ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 168-190.	2.7	46
44	ARIAâ€”EAACI statement on asthma and COVID-19 (June 2, 2020). Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 689-697.	2.7	57
45	COVID-19: A series of important recent clinical and laboratory reports in immunology and pathogenesis of SARS-CoV-2 infection and care of allergy patients. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 622-625.	2.7	11
46	Efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis: A systematic review for the EAACI biologicals guidelines. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 45-58.	2.7	41
47	Cabbage and fermented vegetables: From death rate heterogeneity in countries to candidates for mitigation strategies of severe COVID-19. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 735-750.	2.7	83
48	Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria: A systematic review for the EAACI Biologicals Guidelines. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 59-70.	2.7	58
49	Clinical, radiological, and laboratory characteristics and risk factors for severity and mortality of 289 hospitalized COVID-19 patients. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 533-550.	2.7	149
50	Trained immunity and tolerance in innate lymphoid cells, monocytes, and dendritic cells during allergen-specific immunotherapy. Journal of Allergy and Clinical Immunology, 2021, 147, 1865-1877.	1.5	61
51	Management of patients with chronic rhinosinusitis during the COVID-19 pandemicâ€”An EAACI position paper. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 677-688.	2.7	33
52	Risk factors for severe and critically ill COVID-19 patients: A review. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 428-455.	2.7	904
53	The inspirational journey of Chinese scholars in the field of allergy. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 422-424.	2.7	0
54	Distinct expression of SARS-CoV-2 receptor ACE2 correlates with endotypes of chronic rhinosinusitis with nasal polyps. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 789-803.	2.7	29

#	ARTICLE	IF	CITATIONS
55	Inhibition of CpG methylation improves the barrier integrity of bronchial epithelial cells in asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 1864-1868.	2.7	12
56	An Exopolysaccharide Produced by Bifidobacterium longum 35624Â® Inhibits Osteoclast Formation via a TLR2-Dependent Mechanism. Calcified Tissue International, 2021, 108, 654-666.	1.5	17
57	Potential Interplay between Nrf2, TRPA1, and TRPV1 in Nutrients for the Control of COVID-19. International Archives of Allergy and Immunology, 2021, 182, 324-338.	0.9	33
58	Innate lymphoid cells: The missing part of a puzzle in food allergy. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 2002-2016.	2.7	18
59	Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: A systematic review for the EAACI guidelines. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 2337-2353.	2.7	78
60	Mesenchymal Stem Cells Regulate Type 2 Innate Lymphoid Cells via Regulatory T Cells through ICOS-ICOSL Interaction. Stem Cells, 2021, 39, 975-987.	1.4	15
61	Does the epithelial barrier hypothesis explain the increase in allergy, autoimmunity and other chronic conditions?. Nature Reviews Immunology, 2021, 21, 739-751.	10.6	452
62	Differentiation of COVID-19 signs and symptoms from allergic rhinitis and common cold: An ARIA-EEAACI-EGA²LEN consensus. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 2354-2366.	2.7	31
63	Adherence to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) checklist in articles published in EAACI Journals: A bibliographic study. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 3581-3588.	2.7	5
64	Electrical impedance spectroscopy for the characterization of skin barrier in atopic dermatitis. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 3066-3079.	2.7	33
65	Allergenic components of the mRNA-1273 vaccine for COVID-19: Possible involvement of polyethylene glycol and IgG-mediated complement activation. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 3307-3313.	2.7	92
66	COVID-19 vaccines and the role of other potential allergenic components different from PEG. A reply to: "Other excipients than PEG might cause serious hypersensitivity reactions in COVID-19 vaccines". Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 1943-1944.	2.7	12
67	Vaccines and allergic reactions: The past, the current COVID-19 pandemic, and future perspectives. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 1640-1660.	2.7	72
68	COVID-19 vaccine anaphylaxis: IgE, complement or what else? A reply to: "COVID-19 vaccine anaphylaxis: PEG or not?". Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 1938-1940.	2.7	24
69	Loss of regulatory capacity in Treg cells following rhinovirus infection. Journal of Allergy and Clinical Immunology, 2021, 148, 1016-1029.e16.	1.5	13
70	ARIA-EEAACI statement on severe allergic reactions to COVID-19 vaccines "An EAACI-ARIA Position Paper. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 1624-1628.	2.7	66
71	Spermidine and spermine exert protective effects within the lung. Pharmacology Research and Perspectives, 2021, 9, e00837.	1.1	31
72	Inhaled corticosteroids in early COVID-19: A tale of many facets. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 3540-3542.	2.7	3

#	ARTICLE	IF	CITATIONS
73	Persistent human bocavirus 1 infection and tonsillar immune responses. <i>Clinical and Translational Allergy</i> , 2021, 11, e12030.	1.4	6
74	Advances and highlights in asthma in 2021. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 3390-3407.	2.7	75
75	Management of anaphylaxis due to COVID-19 vaccines in the elderly. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 2952-2964.	2.7	16
76	Advances and highlights in biomarkers of allergic diseases. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 3659-3686.	2.7	84
77	Dysregulation of the epithelial barrier by environmental and other exogenous factors. <i>Contact Dermatitis</i> , 2021, 85, 615-626.	0.8	35
78	Assessment of Allergic and Anaphylactic Reactions to mRNA COVID-19 Vaccines With Confirmatory Testing in a US Regional Health System. <i>JAMA Network Open</i> , 2021, 4, e2125524.	2.8	103
79	Non-immunoglobulin E-mediated allergy associated with Pfizer-BioNTech coronavirus disease 2019 vaccine excipient polyethylene glycol. <i>Annals of Allergy, Asthma and Immunology</i> , 2021, 127, 694-696.	0.5	10
80	Recent advances and developments in COVID-19 in the context of allergic diseases. <i>Clinical and Translational Allergy</i> , 2021, 11, e12065.	1.4	7
81	EAACI Biologicals Guidelines dupilumab for children and adults with moderate-to-severe atopic dermatitis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 988-1009.	2.7	24
82	IL-33 receptor expression on myeloid and plasmacytoid dendritic cells after allergen challenge in patients with allergic rhinitis. <i>International Immunopharmacology</i> , 2021, 101, 108233.	1.7	5
83	Machine Learning-Based Deep Phenotyping of Atopic Dermatitis. <i>JAMA Dermatology</i> , 2021, 157, 1414.	2.0	23
84	Food allergy across the globe. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 148, 1347-1364.	1.5	115
85	Mouse Models of Asthma: Characteristics, Limitations and Future Perspectives on Clinical Translation. <i>Advances in Experimental Medicine and Biology</i> , 2021, , 119-133.	0.8	5
86	Butyrate Inhibits Osteoclast Activity In Vitro and Regulates Systemic Inflammation and Bone Healing in a Murine Osteotomy Model Compared to Antibiotic-Treated Mice. <i>Mediators of Inflammation</i> , 2021, 1-17.	1.4	17
87	Impact of high-altitude therapy on type 2 immune responses in asthma patients. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 84-94.	2.7	28
88	Nanoparticle-Coupled Topical Methotrexate Can Normalize Immune Responses and Induce Tissue Remodeling in Psoriasis. <i>Journal of Investigative Dermatology</i> , 2020, 140, 1003-1014.e8.	0.3	25
89	Pollen exposure weakens innate defense against respiratory viruses. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 576-587.	2.7	84
90	EAACI position paper on diet diversity in pregnancy, infancy and childhood: Novel concepts and implications for studies in allergy and asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 497-523.	2.7	101

#	ARTICLE	IF	CITATIONS
91	Recent developments and advances in atopic dermatitis and food allergy. <i>Allergology International</i> , 2020, 69, 204-214.	1.4	43
92	Highlights of Novel Vaccination Strategies in Allergen Immunotherapy. <i>Immunology and Allergy Clinics of North America</i> , 2020, 40, 15-24.	0.7	17
93	Mechanisms of Subcutaneous and Sublingual Aeroallergen Immunotherapy. <i>Immunology and Allergy Clinics of North America</i> , 2020, 40, 1-14.	0.7	42
94	Skin barrier damage after exposure to paraphenylenediamine. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 619-631.e2.	1.5	21
95	Allergy: New editorial team, innovative content and achievements after two years. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 740-742.	2.7	0
96	Initial butyrate producers during infant gut microbiota development are endospore formers. <i>Environmental Microbiology</i> , 2020, 22, 3909-3921.	1.8	49
97	Global warming, climate change, air pollution and allergies. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2158-2160.	2.7	56
98	Tolerance mechanisms in allergen immunotherapy. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2020, 20, 591-601.	1.1	31
99	Intranasal <i>Bifidobacterium longum</i> protects against viral-induced lung inflammation and injury in a murine model of lethal influenza infection. <i>EBioMedicine</i> , 2020, 60, 102981.	2.7	47
100	Biomarkers for diagnosis and prediction of therapy responses in allergic diseases and asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 3039-3068.	2.7	127
101	Nrf2-interacting nutrients and COVID-19: time for research to develop adaptation strategies. <i>Clinical and Translational Allergy</i> , 2020, 10, 58.	1.4	56
102	Transferability and curability of allergic disease by allogeneic hematopoietic stem cell transplantation. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2392-2394.	2.7	0
103	A novel proangiogenic B cell subset is increased in cancer and chronic inflammation. <i>Science Advances</i> , 2020, 6, eaaz3559.	4.7	36
104	Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1564-1581.	2.7	828
105	Particulate Matter 2.5 Causes Deficiency in Barrier Integrity in Human Nasal Epithelial Cells. <i>Allergy, Asthma and Immunology Research</i> , 2020, 12, 56.	1.1	81
106	Allergen Immunotherapy in Children User's Guide. <i>Pediatric Allergy and Immunology</i> , 2020, 31, 1-101.	1.1	169
107	Increased antiviral response in circulating lymphocytes from hypogammaglobulinemia patients. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 3147-3158.	2.7	4
108	A compendium answering 150 questions on COVID-19 and SARS-CoV-2. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2503-2541.	2.7	95

#	ARTICLE	IF	CITATIONS
109	Distribution of ACE2, CD147, CD26, and other SARSâ€CoVâ€2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVIDâ€19 risk factors. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2829-2845.	2.7	403
110	Environmental factors in epithelial barrier dysfunction. Journal of Allergy and Clinical Immunology, 2020, 145, 1517-1528.	1.5	162
111	Considerations on biologicals for patients with allergic disease in times of the COVIDâ€19 pandemic: An EAACI statement. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2764-2774.	2.7	75
112	T cell requirement and phenotype stability of house dust miteâ€induced neutrophil airway inflammation in mice. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2970-2973.	2.7	3
113	Is diet partly responsible for differences in COVID-19 death rates between and within countries?. Clinical and Translational Allergy, 2020, 10, 16.	1.4	97
114	Transfer and loss of allergenâ€specific responses via stem cell transplantation: A prospective observational study. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2243-2253.	2.7	3
115	Cumulative Lifetime Burden of Cardiovascular Disease From Early Exposure to Air Pollution. Journal of the American Heart Association, 2020, 9, e014944.	1.6	59
116	Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelinesâ€Recommendations on the use of biologicals in severe asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1058-1068.	2.7	67
117	Eleven faces of coronavirus disease 2019. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1699-1709.	2.7	261
118	Intranasal corticosteroids in allergic rhinitis in COVIDâ€19 infected patients: An ARIAâ€EAACI statement. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2440-2444.	2.7	114
119	Immunology of COVIDâ€19: Mechanisms, clinical outcome, diagnostics, and perspectivesâ€A report of the European Academy of Allergy and Clinical Immunology (EAACI). Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2445-2476.	2.7	132
120	Enhancing Data Reliability in TOMAHAQ for Largeâ€Scale Protein Quantification. Proteomics, 2020, 20, e1900105.	1.3	4
121	Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab) Tj ETQq1 1 0.784314 rgBT /C... recommendations on the use of biologicals in severe asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1023-1042.	2.7	232
122	Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines â€recommendations on the use of biologicals in severe asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1043-1057.	2.7	85
123	Clinical characteristics of 140 patients infected with SARSâ€CoVâ€2 in Wuhan, China. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1730-1741.	2.7	2,956
124	Atopic dermatitis in a cohort of West Highland white terriers in Switzerland. Part II: estimates of early life factors and heritability. Veterinary Dermatology, 2020, 31, 276.	0.4	4
125	Unraveling the complexity of atopic dermatitis: The CKâ€CARE approach toward precision medicine. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2936-2938.	2.7	31
126	EAACI Research and Outreach Committee: Improving standards and facilitating global collaboration through a Research Excellence Network. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1899-1901.	2.7	3

#	ARTICLE	IF	CITATIONS
127	A novel whole blood gene expression signature for asthma, dermatitis, and rhinitis multimorbidity in children and adolescents. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 3248-3260.	2.7	55
128	Distinct characteristics of COVID-19 patients with initial rRT-PCR positive and rRT-PCR negative results for SARS-CoV-2. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1809-1812.	2.7	80
129	Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI statement. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1546-1554.	2.7	87
130	Tonsillar microbial diversity, abundance, and interrelations in atopic and non-atopic individuals. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2133-2135.	2.7	5
131	Type 2 immunity in the skin and lungs. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1582-1605.	2.7	304
132	Mechanisms of allergen-specific immunotherapy and allergen tolerance. <i>Allergology International</i> , 2020, 69, 549-560.	1.4	92
133	Outside-in hypothesis revisited. <i>Annals of Allergy, Asthma and Immunology</i> , 2020, 125, 517-527.	0.5	19
134	Advances and recent developments in asthma in 2020. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 3124-3146.	2.7	94
135	Allergen immunotherapy in the current COVID-19 pandemic: A position paper of AeDA, ARIA, EAACI, DGAKI and GPA. <i>Allergologie Select</i> , 2020, 4, 44-52.	1.6	23
136	Use of biologicals in allergic and type-2 inflammatory diseases during the current COVID-19 pandemic. <i>Allergologie Select</i> , 2020, 4, 53-68.	1.6	38
137	Pathophysiology of Allergic Rhinitis. , 2020, , 261-296.		2
138	Influence of Innate Immunity on Immune Tolerance. <i>Acta Medica Academica</i> , 2020, 49, 164-180.	0.3	6
139	Impaired memory B-cell development and antibody maturation with a skewing toward IgE in patients with STAT3 hyper-IgE syndrome. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 2394-2405.	2.7	30
140	Acute Respiratory Barrier Disruption by Ozone Exposure in Mice. <i>Frontiers in Immunology</i> , 2019, 10, 2169.	2.2	55
141	Food and drug allergy, and anaphylaxis in EAACI journals (2018). <i>Pediatric Allergy and Immunology</i> , 2019, 30, 785-794.	1.1	11
142	Immunologic mechanisms in asthma. <i>Seminars in Immunology</i> , 2019, 46, 101333.	2.7	291
143	Highlights and recent developments in airway diseases in EAACI journals (2018). <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 2329-2341.	2.7	9
144	Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases. <i>Clinical and Translational Allergy</i> , 2019, 9, 44.	1.4	87

#	ARTICLE	IF	CITATIONS
145	Human type 2 innate lymphoid cells disrupt skin keratinocyte tight junction barrier by IL-13. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 2534-2537.	2.7	36
146	Blocking histone deacetylase activity as a novel target for epithelial barrier defects in patients with allergic rhinitis. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 1242-1253.e7.	1.5	74
147	Future research trends in understanding the mechanisms underlying allergic diseases for improved patient care. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 2293-2311.	2.7	76
148	EAACI Guidelines on Allergen Immunotherapy: House dust mite-driven allergic asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 855-873.	2.7	191
149	EAACI position paper: Influence of dietary fatty acids on asthma, food allergy, and atopic dermatitis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 1429-1444.	2.7	103
150	miR-10a-5p is increased in atopic dermatitis and has capacity to inhibit keratinocyte proliferation. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 2146-2156.	2.7	31
151	Direct assessment of skin epithelial barrier by electrical impedance spectroscopy. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 1934-1944.	2.7	36
152	Gene expression signatures of circulating human type 1, 2, and 3 innate lymphoid cells. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 2321-2325.	1.5	24
153	Human bocaviruses and paediatric infections. <i>The Lancet Child and Adolescent Health</i> , 2019, 3, 418-426.	2.7	65
154	Immunological methods for diagnosis and monitoring of IgE-mediated allergy caused by industrial sensitizing agents (IMExAllergy). <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 1885-1897.	2.7	16
155	Blocking Histone Deacetylase Activity As A Novel Target For Epithelial Barrier Defects In Allergic Rhinitis. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, AB85.	1.5	1
156	Allergen immunotherapy for IgE-mediated food allergy: There is a measure in everything to a proper proportion of therapy. <i>Pediatric Allergy and Immunology</i> , 2019, 30, 415-422.	1.1	24
157	Development of antirhinoviral DNAzymes for effective prevention of asthma exacerbations. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, AB99.	1.5	0
158	Induction of human regulatory innate lymphoid cells from group 2 innate lymphoid cells by retinoic acid. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 2190-2201.e9.	1.5	133
159	IL-10 producing T and B cells in allergy. <i>Seminars in Immunology</i> , 2019, 44, 101326.	2.7	70
160	Perspectives in allergen immunotherapy: 2019 and beyond. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 3-25.	2.7	113
161	Obesity and disease severity magnify disturbed microbiome-immune interactions in asthma patients. <i>Nature Communications</i> , 2019, 10, 5711.	5.8	141
162	Rhinovirus species and tonsillar immune responses. <i>Clinical and Translational Allergy</i> , 2019, 9, 63.	1.4	3

#	ARTICLE	IF	CITATIONS
163	The Influence of Dietary Fatty Acids on Immune Responses. <i>Nutrients</i> , 2019, 11, 2990.	1.7	181
164	Control of Confounding and Reporting of Results in Causal Inference Studies. Guidance for Authors from Editors of Respiratory, Sleep, and Critical Care Journals. <i>Annals of the American Thoracic Society</i> , 2019, 16, 22-28.	1.5	458
165	Laundry detergents and detergent residue after rinsing directly disrupt tight junction barrier integrity in human bronchial epithelial cells. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 1892-1903.	1.5	96
166	Bacterial secretion of histamine within the gut influences immune responses within the lung. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 899-909.	2.7	58
167	Comparison of regulatory B cells in asthma and allergic rhinitis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 815-818.	2.7	23
168	Role of Der p 1-specific B cells in immune tolerance during 2 years of house dust mite-specific immunotherapy. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 1077-1086.e10.	1.5	67
169	High levels of butyrate and propionate in early life are associated with protection against atopy. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 799-809.	2.7	327
170	Der p 1-specific regulatory T cell response during house dust mite allergen immunotherapy. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 976-985.	2.7	60
171	Key Points for Moving the Endotypes Field Forward. , 2019, , 107-114.		2
172	Development and characterization of DNzyme candidates demonstrating significant efficiency against human rhinoviruses. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 1403-1415.	1.5	23
173	Tight junction, mucin, and inflammasome-related molecules are differentially expressed in eosinophilic, mixed, and neutrophilic experimental asthma in mice. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 294-307.	2.7	109
174	Precision medicine and phenotypes, endotypes, genotypes, regiotypes, and theratypes of allergic diseases. <i>Journal of Clinical Investigation</i> , 2019, 129, 1493-1503.	3.9	197
175	International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis. <i>International Forum of Allergy and Rhinology</i> , 2018, 8, 108-352.	1.5	273
176	Ozone exposure induces respiratory barrier biphasic injury and inflammation controlled by IL-33. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 942-958.	1.5	93
177	A Fluorescent Probe to Unravel Functional Features of Cannabinoid Receptor CB ₁ in Human Blood and Tonsil Immune System Cells. <i>Bioconjugate Chemistry</i> , 2018, 29, 382-389.	1.8	26
178	Treatment for food allergy. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 1-9.	1.5	139
179	Mechanisms of food allergy. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 11-19.	1.5	212
180	Food allergy: Update on prevention and tolerance. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 30-40.	1.5	104

#	ARTICLE	IF	CITATIONS
181	Staphylococcus aureus enhances the tight junction barrier integrity in healthy nasal tissue, but not in nasal polyps. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 665-668.e8.	1.5	30
182	Type 2 innate lymphoid cells disrupt bronchial epithelial barrier integrity by targeting tight junctions through IL-13 in asthmatic patients. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 300-310.e11.	1.5	182
183	Exposure to nonmicrobial N-glycolylneuraminic acid protects farmers' children against airway inflammation and colitis. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 382-390.e7.	1.5	44
184	Monitoring inflammatory heterogeneity with multiple biomarkers for multidimensional endotyping of asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 442-445.	1.5	33
185	Evanescence wave-based technology for the rapid and sensitive quantification of biological analytes. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 817-820.e5.	1.5	1
186	Histamine and T helper cytokine-driven epithelial barrier dysfunction in allergic rhinitis. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 951-963.e8.	1.5	139
187	Human CD40 ligand-expressing type 3 innate lymphoid cells induce IL-10-producing immature transitional regulatory B cells. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 178-194.e11.	1.5	46
188	Specific allergy and asthma prevention coming to an age: A milestone in children. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 527-528.	1.5	1
189	Transforming growth factor- β 21 decreases epithelial tight junction integrity in chronic rhinosinusitis with nasal polyps. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 1160-1163.e9.	1.5	27
190	â/2é™...è•â,žé¼¼»çš-â...±è°æ : ââ°»æšé¼¼»ç,ž. <i>International Forum of Allergy and Rhinology</i> , 2018, 8, 108-35224		
191	Highlights and recent developments in food and drug allergy, and anaphylaxis in EAACI Journals (2017). <i>Pediatric Allergy and Immunology</i> , 2018, 29, 801-807.	1.1	8
192	Precision/Personalized Medicine in Allergic Diseases and Asthma. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2018, 66, 431-442.	1.0	13
193	Chronic rhinosinusitis: pathogenesis, therapy options, and more. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1805-1815.	0.9	33
194	Tonsillar cytokine expression between patients with tonsillar hypertrophy and recurrent tonsillitis. <i>Clinical and Translational Allergy</i> , 2018, 8, 22.	1.4	17
195	micro<sc>RNA</sc>-46a is linked to the production of IgE in mice but not in atopic dermatitis patients. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 2400-2403.	2.7	12
196	Provocative proposal for a revised nomenclature for allergy and other hypersensitivity diseases. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 1939-1940.	2.7	10
197	Microbiome and asthma. <i>Asthma Research and Practice</i> , 2018, 4, 1.	1.2	117
198	Relations between epidermal barrier dysregulation and Staphylococcus species-dominated microbiome dysbiosis in patients with atopic dermatitis. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 1643-1647.e12.	1.5	56

#	ARTICLE	IF	CITATIONS
199	The role of environmental factors in allergy: A critical reappraisal. <i>Experimental Dermatology</i> , 2018, 27, 1193-1200.	1.4	60
200	The concepts of asthma endotypes and phenotypes to guide current and novel treatment strategies. <i>Expert Review of Respiratory Medicine</i> , 2018, 12, 733-743.	1.0	32
201	Introduction to Mechanisms of Allergic Diseases. , 2017, , 1-27.		5
202	Regulation of bronchial epithelial barrier integrity by type 2 cytokines and histone deacetylases in asthmatic patients. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 93-103.	1.5	154
203	Mast Cells Suppress IL-33 Induced Innate-Type Allergic Airway Inflammation By Promoting Regulatory T Cell Expansion. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, AB165.	1.5	0
204	Mechanisms of the Development of Allergy (MeDALL): Introducing novel concepts in allergy phenotypes. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 388-399.	1.5	145
205	A Novel Human Effector B cell Subset. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, AB14.	1.5	0
206	Clinical phenotypes and endophenotypes of atopic dermatitis: Where are we, and where should we go?. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, S58-S64.	1.5	229
207	Type 3 innate lymphoid cells induce proliferation of CD94+ natural killer cells. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 1156-1159.e7.	1.5	1
208	The future of allergy/immunology: Promising young investigators. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 384-386.	1.5	2
209	Asthma research in Europe: a transformative agenda for innovation and competitiveness. <i>European Respiratory Journal</i> , 2017, 49, 1602294.	3.1	7
210	Precision Medicine in Allergic Disorders. <i>Current Treatment Options in Allergy</i> , 2017, 4, 283-285.	0.9	1
211	miR-146b Probably Assists miRNA-146a in the Suppression of Keratinocyte Proliferation and Inflammatory Responses in Psoriasis. <i>Journal of Investigative Dermatology</i> , 2017, 137, 1945-1954.	0.3	68
212	The effects of cryopreservation on the expression of canine regulatory T-cell markers. <i>Veterinary Dermatology</i> , 2017, 28, 396-e93.	0.4	4
213	Advances and highlights in allergen immunotherapy: On the way to sustained clinical and immunologic tolerance. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 1250-1267.	1.5	94
214	Immune regulation by histamine and histamine-secreting bacteria. <i>Current Opinion in Immunology</i> , 2017, 48, 108-113.	2.4	89
215	Tumour-derived PGD2 and Nkp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis. <i>Nature Communications</i> , 2017, 8, 593.	5.8	175
216	Allergen immunotherapy for allergic asthma: a systematic overview of systematic reviews. <i>Clinical and Translational Allergy</i> , 2017, 7, 25.	1.4	56

#	ARTICLE	IF	CITATIONS
217	A wide diversity of bacteria from the human gut produces and degrades biogenic amines. <i>Microbial Ecology in Health and Disease</i> , 2017, 28, 1353881.	3.8	107
218	Highlights in immune response, microbiome and precision medicine in allergic disease and asthma. <i>Current Opinion in Immunology</i> , 2017, 48, iv-ix.	2.4	15
219	The Journal of Allergy and Clinical Immunology : An update on style and substance. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 60-62.	1.5	0
220	Mechanisms of immune regulation in allergic diseases: the role of regulatory T and B cells. <i>Immunological Reviews</i> , 2017, 278, 219-236.	2.8	234
221	Segmental duplications and evolutionary acquisition of UV damage response in the SPATA31 gene family of primates and humans. <i>BMC Genomics</i> , 2017, 18, 222.	1.2	8
222	Validation of the Global Allergy and Asthma European Network (GA 2 LEN) chamber for trials in allergy: Innovation of a mobile allergen exposure chamber. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 1158-1166.	1.5	32
223	<i>Allergy and Inflammation.</i> , 2017, , 995-1030.		0
224	European Summit on the Prevention and Self-Management of Chronic Respiratory Diseases: report of the European Union Parliament Summit (29 March 2017). <i>Clinical and Translational Allergy</i> , 2017, 7, 49.	1.4	48
225	Rhinovirus triggers increased inflammasome activation in human bronchial epithelium in asthma. , 2017, , .		3
226	The relationship of serum vitamins A, D, E and LL-37 levels with allergic status, tonsillar virus detection and immune response. <i>PLoS ONE</i> , 2017, 12, e0172350.	1.1	35
227	Distinctive gene signature of allergen-specific CD4+T cells in allergic patients. , 2017, , .		0
228	Monitoring the inflammatory heterogeneity in asthma with multiple biomarkers for multidimensional endotyping. , 2017, , .		0
229	Comprehensive characterization of asthma patients using the Bayesian Network Model. , 2017, , .		0
230	Genome Analysis and Characterisation of the Exopolysaccharide Produced by <i>Bifidobacterium longum</i> subsp. <i>longum</i> 35624â„¢. <i>PLoS ONE</i> , 2016, 11, e0162983.	1.1	76
231	Allergen immunotherapy for IgE-mediated food allergy: protocol for a systematic review. <i>Clinical and Translational Allergy</i> , 2016, 6, 24.	1.4	17
232	Phenotypes and Emerging Endotypes of Chronic Rhinosinusitis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2016, 4, 621-628.	2.0	180
233	MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 367-374.e2.	1.5	128
234	Advances and highlights in mechanisms of allergic disease in 2015. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 1681-1696.	1.5	35

#	ARTICLE	IF	CITATIONS
235	Precision medicine in patients with allergic diseases: Airway diseases and atopic dermatitisâ€”PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 1347-1358.	1.5	249
236	Precision medicine and precision health: Building blocks to foster a revolutionary health care model. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 1359-1361.	1.5	26
237	Novel Biologicals for the Treatment of Allergic Diseases and Asthma. <i>Current Allergy and Asthma Reports</i> , 2016, 16, 70.	2.4	56
238	Anionic surfactants and commercial detergents decrease tight junction barrier integrity in human keratinocytes. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 890-893.e9.	1.5	67
239	Platelet-activating factor decreases skin keratinocyte tight junction barrier integrity. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 1725-1728.e3.	1.5	7
240	Cellular and molecular immunologic mechanisms in patients with atopic dermatitis. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 336-349.	1.5	465
241	Histamine-secreting microbes are increased in the gut of adult asthma patients. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 1491-1494.e7.	1.5	109
242	Interleukins (from IL-1 to IL-38), interferons, transforming growth factor Î², and TNF-Î±: Receptors, functions, and roles in diseases. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 984-1010.	1.5	612
243	TGFÎ². , 2016, , 563-571.		0
244	The Surface-Associated Exopolysaccharide of <i>Bifidobacterium longum</i> 35624 Plays an Essential Role in Dampening Host Proinflammatory Responses and Repressing Local T _H 17 Responses. <i>Applied and Environmental Microbiology</i> , 2016, 82, 7185-7196.	1.4	126
245	Histamine Receptor 2 is Required to Suppress Innate Immune Responses to Bacterial Ligands in Patients with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 1575-1586.	0.9	33
246	Endotypes of allergic diseases and asthma: An important step in building blocks for the future of precision medicine. <i>Allergology International</i> , 2016, 65, 243-252.	1.4	151
247	Prostaglandin E2 and lipoxin A4 inÂPBMCs are associated with immune tolerance during venom immunotherapy. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 1199-1202.e2.	1.5	7
248	Impaired barrier function in patients with house dust miteâ€”induced allergic rhinitis is accompanied by decreased occludin and zonula occludens-1 expression. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 1043-1053.e5.	1.5	244
249	Allergen immunotherapy for allergic asthma: protocol for a systematic review. <i>Clinical and Translational Allergy</i> , 2016, 6, 5.	1.4	15
250	Myocardial expression profiles of candidate molecules in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia compared to those with dilated cardiomyopathy and healthy controls. <i>Heart Rhythm</i> , 2016, 13, 731-741.	0.3	32
251	Consensus Communication on Early Peanut Introduction and Prevention of Peanut Allergy in Highâ€Risk Infants. <i>Pediatric Dermatology</i> , 2016, 33, 103-106.	0.5	36
252	International Consensus on Allergen Immunotherapy II: Mechanisms, standardization, and pharmacoconomics. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 358-368.	1.5	199

#	ARTICLE	IF	CITATIONS
253	A new beginning: Building on the past, looking to the future. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 46-47.	1.5	2
254	Innate mechanisms can predict successful allergy immunotherapy. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 559-561.	1.5	11
255	Mechanisms of Aeroallergen Immunotherapy. <i>Immunology and Allergy Clinics of North America</i> , 2016, 36, 71-86.	0.7	28
256	Immunology of the Asthmatic Response. , 2016, , 250-261.e5.		1
257	Serum IL-5 and IL-13 consistently serve as the best predictors for the blood eosinophilia phenotype in adult asthmatics. , 2016, , .		0
258	Allergen immunotherapy for insect venom allergy: protocol for a systematic review. <i>Clinical and Translational Allergy</i> , 2015, 6, 6.	1.4	11
259	Rhinovirus infection has allergen-specific tolerance-breaking effects on PBMCs of healthy individuals. <i>World Allergy Organization Journal</i> , 2015, 8, A257.	1.6	2
260	A review of the value of innovation in inhalers for COPD and asthma. <i>Journal of Market Access & Health Policy</i> , 2015, 3, 28760.	0.8	19
261	Asthma, allergy and the Olympics. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2015, 15, 184-192.	1.1	66
262	Mechanisms of allergen-specific immunotherapy and immune tolerance to allergens. <i>World Allergy Organization Journal</i> , 2015, 8, 17.	1.6	248
263	T-cell regulation during viral and nonviral asthma exacerbations. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 194-197.e9.	1.5	21
264	Consensus communication on early peanut introduction and the prevention of peanut allergy in high-risk infants. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 258-261.	1.5	162
265	In lasting tribute: Professor Dr IÅil Berat Barlan (1958-2015). <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 215.	1.5	0
266	Consensus communication on early peanut introduction and the prevention of peanut allergy in high-risk infants. <i>Annals of Allergy, Asthma and Immunology</i> , 2015, 115, 87-90.	0.5	26
267	International consensus on allergy immunotherapy. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 556-568.	1.5	427
268	The Complex Type 2 Endotype in Allergy and Asthma: From Laboratory to Bedside. <i>Current Allergy and Asthma Reports</i> , 2015, 15, 29.	2.4	65
269	An Interleukin-33-Mast Cell-Interleukin-2 Axis Suppresses Papain-Induced Allergic Inflammation by Promoting Regulatory T Cell Numbers. <i>Immunity</i> , 2015, 43, 175-186.	6.6	240
270	CpG-DNA enhances the tight junction integrity of the bronchial epithelial cell barrier. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 1413-1416.e8.	1.5	30

#	ARTICLE	IF	CITATIONS
271	Advances in allergen immunotherapy: Aiming for complete tolerance to allergens. <i>Science Translational Medicine</i> , 2015, 7, 280ps6.	5.8	102
272	Consensus Communication on Early Peanut Introduction and the Prevention of Peanut Allergy in High-risk Infants. <i>Pediatrics</i> , 2015, 136, 600-604.	1.0	23
273	The expression of gingival epithelial junctions in response to subgingival biofilms. <i>Virulence</i> , 2015, 6, 704-709.	1.8	32
274	IL-10â€œoverexpressing B cells regulate innate and adaptive immune responses. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, 771-780.e8.	1.5	123
275	The Induction of IL-33 in the Sinus Epithelium and Its Influence on T-Helper Cell Responses. <i>PLoS ONE</i> , 2015, 10, e0123163.	1.1	22
276	Differential serum protein markers and the clinical severity of asthma. <i>Journal of Asthma and Allergy</i> , 2014, 7, 67.	1.5	21
277	Defining adult asthma endotypes by clinical features and patterns of volatile organic compounds in exhaled air. <i>Respiratory Research</i> , 2014, 15, 136.	1.4	41
278	Differential expression of IL-33 and HMGB1 in the lungs of stable cystic fibrosis patients. <i>European Respiratory Journal</i> , 2014, 44, 802-805.	3.1	35
279	Novel NLRP3/cryopyrin mutations and pro-inflammatory cytokine profiles in Behçetâ€™s syndrome patients. <i>International Immunology</i> , 2014, 26, 71-81.	1.8	34
280	In utero priming by worms protects against respiratory allergies. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 134, 1280-1281.	1.5	12
281	Novel immunotherapy vaccine development. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2014, 14, 557-563.	1.1	28
282	Categorization of allergic disorders in the new World Health Organization International Classification of Diseases. <i>Clinical and Translational Allergy</i> , 2014, 4, 42.	1.4	54
283	The expression of cannabinoid receptor 1 is significantly increased in atopic patients. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 926-929.e2.	1.5	20
284	MicroRNAs in Allergy and Asthma. <i>Current Allergy and Asthma Reports</i> , 2014, 14, 424.	2.4	60
285	IL-33â€œDependent Type 2 Inflammation during Rhinovirus-induced Asthma Exacerbations <i>In Vivo</i> . <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 190, 1373-1382.	2.5	500
286	Histamine receptor 2 is a key influence in immune responses to intestinal histamine-secreting microbes. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 134, 744-746.e3.	1.5	62
287	Modulation of immune responses by immunotherapy in allergic diseases. <i>Current Opinion in Pharmacology</i> , 2014, 17, 30-37.	1.7	39
288	Th2-Type Cytokineâ€œInduced Mucus Metaplasia Decreases Susceptibility of Human Bronchial Epithelium to Rhinovirus Infection. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2014, 51, 229-241.	1.4	51

#	ARTICLE	IF	CITATIONS
289	MicroRNA-146a alleviates chronic skin inflammation in atopic dermatitis through suppression of innate immune responses in keratinocytes. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 134, 836-847.e11.	1.5	152
290	Sputum Cytokines and Adult Asthma Endotypes. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, AB399.	1.5	0
291	Mechanisms of allergen-specific immunotherapy: Multiple suppressor factors at work in immune tolerance to allergens. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 621-631.	1.5	481
292	Mechanisms of immune tolerance to allergens: role of IL-10 and Tregs. <i>Journal of Clinical Investigation</i> , 2014, 124, 4678-4680.	3.9	160
293	The Global Alliance against Respiratory Diseases (GARD) Country Report. <i>Primary Care Respiratory Journal: Journal of the General Practice Airways Group</i> , 2014, 23, 98-101.	2.5	20
294	Scientific Foundations of Allergen-Specific Immunotherapy for Allergic Disease. <i>Chest</i> , 2014, 146, 1347-1357.	0.4	41
295	Expression of Genes Related to Anti-Inflammatory Pathways Are Modified Among Farmersâ€™ Children. <i>PLoS ONE</i> , 2014, 9, e91097.	1.1	40
296	Immune Tolerance. , 2014, , 45-64.		2
297	Histamine and H1 Antihistamines. , 2014, , 1503-1533.		4
298	The biodiversity hypothesis and allergic disease: world allergy organization position statement. <i>World Allergy Organization Journal</i> , 2013, 6, 3.	1.6	282
299	Under the skin or under the tongue: differences and similarities in mechanisms of sublingual and subcutaneous immunotherapy. <i>Immunotherapy</i> , 2013, 5, 1151-1158.	1.0	7
300	IgG4 production is confined to human IL-10â€producing regulatory B cells that suppress antigen-specific immune responses. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 131, 1204-1212.	1.5	516
301	Endotypes and phenotypes of chronic rhinosinusitis: AÂRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 131, 1479-1490.	1.5	470
302	Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 131, 1288-1296.e3.	1.5	396
303	Triggering of specific Toll-like receptors and proinflammatory cytokines breaks allergen-specific T-cell tolerance in human tonsils and peripheral blood. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 131, 875-885.e9.	1.5	76
304	Histamine receptor 2 modifies dendritic cell responses to microbial ligands. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 132, 194-204.e12.	1.5	102
305	Vascular Endothelial Growth Factor as a Key Inducer of Angiogenesis in the Asthmatic Airways. <i>Current Allergy and Asthma Reports</i> , 2013, 13, 1-9.	2.4	74
306	Mechanisms of peripheral tolerance to allergens. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2013, 68, 161-170.	2.7	111

#	ARTICLE	IF	CITATIONS
307	A Th17- and Th2-skewed Cytokine Profile in Cystic Fibrosis Lungs Represents a Potential Risk Factor for <i>Pseudomonas aeruginosa</i> Infection. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 621-629.	2.5	151
308	Suppression of B cell activation and IL-17, IL-17A, IL-17G and IL-17F production by mammalian telomeric oligonucleotides. Allergy: European Journal of Allergy and Clinical Immunology, 2013, 68, 593-603.	2.7	27
309	MicroRNAs: Essential players in the regulation of inflammation. Journal of Allergy and Clinical Immunology, 2013, 132, 15-26.	1.5	180
310	Mechanisms of Allergen-Specific Immunotherapy and Novel Ways for Vaccine Development. Allergology International, 2013, 62, 425-433.	1.4	63
311	Pimecrolimus, a topical calcineurin inhibitor used in the treatment of atopic eczema. Expert Opinion on Drug Metabolism and Toxicology, 2013, 9, 1507-1516.	1.5	6
312	Mechanisms of immune tolerance to allergens in children. Korean Journal of Pediatrics, 2013, 56, 505.	1.9	19
313	Immunomodulation by Bifidobacterium infantis 35624 in the Murine Lamina Propria Requires Retinoic Acid-Dependent and Independent Mechanisms. PLoS ONE, 2013, 8, e62617.	1.1	76
314	Primate segmental duplication creates novel promoters for the LRRC37 gene family within the 17q21.31 inversion polymorphism region. Genome Research, 2012, 22, 1050-1058.	2.4	20
315	Portrait of an immunoregulatory bifidobacterium. Gut Microbes, 2012, 3, 261-266.	4.3	104
316	Novel developments in the mechanisms of immune tolerance to allergens. Human Vaccines and Immunotherapeutics, 2012, 8, 1485-1491.	1.4	6
317	<i>Bifidobacterium infantis</i> 35624 administration induces Foxp3 T regulatory cells in human peripheral blood: potential role for myeloid and plasmacytoid dendritic cells. Gut, 2012, 61, 354-366.	6.1	242
318	Early suppression of basophil activation during allergen-specific immunotherapy by histamine receptor 2. Journal of Allergy and Clinical Immunology, 2012, 130, 1153-1158.e2.	1.5	116
319	We call for iCAALL: International Collaboration for Asthma, Allergy and Immunology. Annals of Allergy, Asthma and Immunology, 2012, 108, 215-216.	0.5	1
320	We Call for iCAALL: International Collaboration in Asthma, Allergy and Immunology. World Allergy Organization Journal, 2012, 5, 39-40.	1.6	12
321	Research needs in allergy: an EAACI position paper, in collaboration with EFA. Clinical and Translational Allergy, 2012, 2, 21.	1.4	127
322	Induction and maintenance of allergen-specific FOXP3+ Treg cells in human tonsils as potential first-line organs of oral tolerance. Journal of Allergy and Clinical Immunology, 2012, 129, 510-520.e9.	1.5	140
323	The suppressive role of IL-10 in contact and atopic dermatitis. Journal of Allergy and Clinical Immunology, 2012, 129, 160-161.	1.5	23
324	Inhibition of angiogenesis by IL-32: Possible role in asthma. Journal of Allergy and Clinical Immunology, 2012, 129, 964-973.e7.	1.5	69

#	ARTICLE	IF	CITATIONS
325	Understanding the complexity of IgE-related phenotypes from childhood to young adulthood: A Mechanisms of the Development of Allergy (MeDALL) Seminar. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 129, 943-954.e4.	1.5	68
326	We call for iCAALL: International Collaboration in Asthma, Allergy and Immunology. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 129, 904-905.	1.5	10
327	Mechanisms of IFN- γ -induced apoptosis of human skin keratinocytes in patients with atopic dermatitis. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 129, 1297-1306.	1.5	128
328	Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 129, 1290-1296.	1.5	236
329	The broad spectrum of interepithelial junctions in skin and lung. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 130, 544-547.e4.	1.5	36
330	Immune response modifiers in the treatment of asthma: A PRACTALL document of the American Academy of Allergy, Asthma & Immunology and the European Academy of Allergy and Clinical Immunology. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 130, 311-324.	1.5	18
331	TH17 and TH22 cells: A confusion of antimicrobial response with tissue inflammation versus protection. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 129, 1438-1449.	1.5	159
332	Defective epithelial barrier in chronic rhinosinusitis: The regulation of tight junctions by IFN- γ and IL-4. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 130, 1087-1096.e10.	1.5	393
333	IgE class switching and cellular memory. <i>Nature Immunology</i> , 2012, 13, 312-314.	7.0	29
334	Histamine regulation of innate and adaptive immunity. <i>Frontiers in Bioscience - Landmark</i> , 2012, 17, 40.	3.0	38
335	Therapies for allergic inflammation: refining strategies to induce tolerance. <i>Nature Medicine</i> , 2012, 18, 736-749.	15.2	261
336	Mechanisms of Immune Tolerance to Allergens. <i>Chemical Immunology and Allergy</i> , 2012, 96, 30-38.	1.7	27
337	Regulatory cells in allergen-specific immunotherapy. <i>Immunotherapy</i> , 2012, 4, 389-396.	1.0	20
338	Clinical Overview of Cutaneous Features in Hypereosinophilic Syndrome. <i>Current Allergy and Asthma Reports</i> , 2012, 12, 85-98.	2.4	32
339	We call for iCAALL: International Collaboration in Asthma, Allergy and Immunology. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2012, 67, 449-450.	2.7	5
340	Regulation and expression of IL-32 in chronic rhinosinusitis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2012, 67, 790-798.	2.7	37
341	Mechanisms of allergen-specific immunotherapy. <i>Clinical and Translational Allergy</i> , 2012, 2, 2.	1.4	154
342	Cord Blood Derived CD4+CD25 ^{high} T Cells Become Functional Regulatory T Cells upon Antigen Encounter. <i>PLoS ONE</i> , 2012, 7, e29355.	1.1	36

#	ARTICLE	IF	CITATIONS
343	Specific immunotherapy and turning off the T cell: how does it work?. <i>Annals of Allergy, Asthma and Immunology</i> , 2011, 107, 381-392.	0.5	27
344	TNF-like weak inducer of apoptosis (TWEAK) and TNF- α cooperate in the induction of keratinocyte apoptosis. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 127, 200-207.e10.	1.5	113
345	Mechanisms of allergen-specific immunotherapy. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 127, 18-27.	1.5	440
346	Asthma endotypes: A new approach to classification of disease entities within the asthma syndrome. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 127, 355-360.	1.5	1,007
347	Interleukins, from 1 to 37, and interferon- γ : Receptors, functions, and roles in diseases. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 127, 701-721.e70.	1.5	650
348	Histamine receptor H1 signaling on dendritic cells plays a key role in the IFN- γ /IL-17 balance in T cell-mediated skin inflammation. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 127, 943-953.e10.	1.5	43
349	Claudin-1 expression in airway smooth muscle exacerbates airway remodeling in asthmatic subjects. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 127, 1612-1621.e8.	1.5	53
350	The many routes of dendritic cells to ensure immune regulation. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 127, 1541-1542.	1.5	15
351	Regulation of the immune response and inflammation by histamine and histamine receptors. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 128, 1153-1162.	1.5	254
352	Regulation of TH17 and regulatory T cells in patients with Behçet disease. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 128, 665-666.	1.5	48
353	Mechanisms of Subcutaneous Allergen Immunotherapy. <i>Immunology and Allergy Clinics of North America</i> , 2011, 31, 175-190.	0.7	35
354	Update in the Mechanisms of Allergen-Specific Immunotherapy. <i>Allergy, Asthma and Immunology Research</i> , 2011, 3, 11.	1.1	52
355	T-cell Subset Regulation in Atopy. <i>Current Allergy and Asthma Reports</i> , 2011, 11, 139-145.	2.4	89
356	IL-33 links tissue cells, dendritic cells and Th2 cell development in a mouse model of asthma. <i>European Journal of Immunology</i> , 2011, 41, 1535-1538.	1.6	91
357	Fighting allergies beyond symptoms: The European Declaration on Immunotherapy. <i>European Journal of Immunology</i> , 2011, 41, 2802-2804.	1.6	12
358	Complementary Human mDC and pDC Mechanisms Ensure Induction of Foxp3+ T Cells in Response to the Commensal Microbiota. <i>American Journal of Gastroenterology</i> , 2011, 106, S478.	0.2	0
359	TRAIL Death Receptor-4, Decoy Receptor-1 and Decoy Receptor-2 Expression on CD8+ T Cells Correlate with the Disease Severity in Patients with Rheumatoid Arthritis. <i>BMC Musculoskeletal Disorders</i> , 2010, 11, 192.	0.8	21
360	Role of Treg in immune regulation of allergic diseases. <i>European Journal of Immunology</i> , 2010, 40, 1232-1240.	1.6	326

#	ARTICLE	IF	CITATIONS
361	RORC2 Is Involved in T Cell Polarization through Interaction with the FOXP3 Promoter. Journal of Immunology, 2010, 184, 6161-6169.	0.4	49
362	T-Cell Response to Allergens. Chemical Immunology and Allergy, 2010, 95, 22-44.	1.7	67
363	IL-32 is expressed by human primary keratinocytes and modulates keratinocyte apoptosis in atopic dermatitis. Journal of Allergy and Clinical Immunology, 2010, 125, 858-865.e10.	1.5	134
364	Novel immunotherapeutic approaches for allergy and asthma. Autoimmunity, 2010, 43, 493-503.	1.2	14
365	Unique Phenotype of Human Tonsillar and In Vitro-Induced FOXP3+CD8+ T Cells. Journal of Immunology, 2009, 182, 2124-2130.	0.4	71
366	Regulation of the <i>foxp3</i> Gene by the Th1 Cytokines: The Role of IL-27-Induced STAT1. Journal of Immunology, 2009, 182, 1041-1049.	0.4	75
367	Therapeutic manipulation of immune tolerance in allergic disease. Nature Reviews Drug Discovery, 2009, 8, 645-660.	21.5	169
368	IL-10 suppresses CD2-mediated T cell activation via SHP-1. Molecular Immunology, 2009, 46, 622-629.	1.0	23
369	Differentiation and functional analysis of human TH17 cells. Journal of Allergy and Clinical Immunology, 2009, 123, 588-595.e7.	1.5	96
370	Mechanisms and treatment of allergic disease in the big picture of regulatory T cells. Journal of Allergy and Clinical Immunology, 2009, 123, 735-746.	1.5	303
371	T cells in health and disease. Journal of Allergy and Clinical Immunology, 2009, 123, 1022-1023.	1.5	14
372	Dual nature of T cell-epithelium interaction in chronic rhinosinusitis. Journal of Allergy and Clinical Immunology, 2009, 124, 74-80.e8.	1.5	53
373	Exploring the repertoire of IgE-binding self-antigens associated with atopic eczema. Journal of Allergy and Clinical Immunology, 2009, 124, 278-285.e7.	1.5	67
374	Transcription factors RUNX1 and RUNX3 in the induction and suppressive function of Foxp3+ inducible regulatory T cells. Journal of Experimental Medicine, 2009, 206, 2701-2715.	4.2	183
375	Modular antigen-translocation as a novel vaccine strategy for allergen-specific immunotherapy. Current Opinion in Allergy and Clinical Immunology, 2009, 9, 568-573.	1.1	21
376	Histamine and H1-Antihistamines. , 2009, , 1517-1547.		4
377	Anaphylaxis: Are Regulatory T Cells the Target of Venom Immunotherapy?. , 2009, , 325-334.		0
378	Role of T cells. , 2009, , 121-147.		1

#	ARTICLE	IF	CITATIONS
379	Immune Regulation by Histamine H4 Receptors in Skin. <i>Journal of Investigative Dermatology</i> , 2008, 128, 1615-1616.	0.3	13
380	The IgE-Reactive Autoantigen Hom s 2 Induces Damage of Respiratory Epithelial Cells and Keratinocytes via Induction of IFN- β . <i>Journal of Investigative Dermatology</i> , 2008, 128, 1451-1459.	0.3	48
381	Increased activation-induced cell death of high IFN- β -producing TH1 cells as a mechanism of TH2 predominance in Atopic diseases. <i>Journal of Allergy and Clinical Immunology</i> , 2008, 121, 652-658.e1.	1.5	93
382	T-cell regulation in chronic paranasal sinus disease. <i>Journal of Allergy and Clinical Immunology</i> , 2008, 121, 1435-1441.e3.	1.5	308
383	New insights into mechanisms of immunoregulation in 2007. <i>Journal of Allergy and Clinical Immunology</i> , 2008, 122, 700-709.	1.5	16
384	Clinical and immunologic effects of H1 antihistamine preventive medication during honeybee venom immunotherapy. <i>Journal of Allergy and Clinical Immunology</i> , 2008, 122, 1001-1007.e4.	1.5	85
385	Nature of Regulatory T Cells in the Context of Allergic Disease. <i>Allergy, Asthma and Clinical Immunology</i> , 2008, 4, 106-10.	0.9	8
386	T-Cell Regulatory Mechanisms in Specific Immunotherapy. <i>Chemical Immunology and Allergy</i> , 2008, 94, 158-177.	1.7	39
387	Regulatory Effects of Histamine and Histamine Receptor Expression in Human Allergic Immune Responses. <i>Chemical Immunology and Allergy</i> , 2008, 94, 67-82.	1.7	36
388	Regulatory NK Cells Suppress Antigen-Specific T Cell Responses. <i>Journal of Immunology</i> , 2008, 180, 850-857.	0.4	215
389	In vivo switch to IL-10-secreting T regulatory cells in high dose allergen exposure. <i>Journal of Experimental Medicine</i> , 2008, 205, 2887-2898.	4.2	431
390	Decoy Receptor-2 Small Interfering RNA (siRNA) Strategy Employing Three Different siRNA Constructs in Combination Defeats Adenovirus-Transferred Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Resistance in Lung Cancer Cells. <i>Human Gene Therapy</i> , 2007, 18, 39-50.	1.4	33
391	Identification of a B-cell Epitope of Hyaluronidase, a Major Bee Venom Allergen, from its Crystal Structure in Complex with a Specific Fab. <i>Journal of Molecular Biology</i> , 2007, 368, 742-752.	2.0	75
392	Mechanisms of allergen-specific immunotherapy. <i>Journal of Allergy and Clinical Immunology</i> , 2007, 119, 780-789.	1.5	336
393	Discontinued drugs in 2006: pulmonary-allergy, dermatological, gastrointestinal and arthritis drugs. <i>Expert Opinion on Investigational Drugs</i> , 2007, 16, 1327-1344.	1.9	6
394	Connective tissue growth factor expression is regulated by histamine in lung fibroblasts: Potential role of histamine in airway remodeling. <i>Journal of Allergy and Clinical Immunology</i> , 2007, 119, 1398-1407.	1.5	44
395	IL-10 inhibits CD28 and ICOS costimulations of T cells via src homology 2 domain-containing protein tyrosine phosphatase 1. <i>Journal of Allergy and Clinical Immunology</i> , 2007, 120, 76-83.	1.5	97
396	TH17 cells in the big picture of immunology. <i>Journal of Allergy and Clinical Immunology</i> , 2007, 120, 247-254.	1.5	227

#	ARTICLE	IF	CITATIONS
397	GATA3-Driven Th2 Responses Inhibit TGF- β 1-Induced FOXP3 Expression and the Formation of Regulatory T Cells. <i>PLoS Biology</i> , 2007, 5, e329.	2.6	245
398	Comparison of Der p1-specific antibody levels in children with allergic airway disease and healthy controls. <i>Pediatric Allergy and Immunology</i> , 2007, 18, 320-325.	1.1	19
399	Mechanisms of Allergen-Specific Immunotherapy: T-Regulatory Cells and More. <i>Immunology and Allergy Clinics of North America</i> , 2006, 26, 207-231.	0.7	41
400	Histamine Receptors in Immune Regulation and Allergen-Specific Immunotherapy. <i>Immunology and Allergy Clinics of North America</i> , 2006, 26, 245-259.	0.7	25
401	Preface. <i>Immunology and Allergy Clinics of North America</i> , 2006, 26, xiii-xxii.	0.7	5
402	Bacillus Calmette-Guerin, Mycobacterium bovis, as an Immunomodulator in Atopic Diseases. <i>Immunology and Allergy Clinics of North America</i> , 2006, 26, 365-377.	0.7	16
403	Absence of T-regulatory cell expression and function in atopic dermatitis skin. <i>Journal of Allergy and Clinical Immunology</i> , 2006, 117, 176-183.	1.5	233
404	Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. <i>Journal of Allergy and Clinical Immunology</i> , 2006, 118, 152-169.	1.5	419
405	Mechanisms of immune suppression by interleukin-10 and transforming growth factor-beta: the role of T regulatory cells. <i>Immunology</i> , 2006, 117, 433-442.	2.0	594
406	Immunological mechanisms of allergen-specific immunotherapy. <i>Nature Reviews Immunology</i> , 2006, 6, 761-771.	10.6	686
407	Allergy and hypersensitivity. <i>Current Opinion in Immunology</i> , 2006, 18, 718-726.	2.4	136
408	T-cell subsets in the pathogenesis of human asthma. <i>Current Allergy and Asthma Reports</i> , 2006, 6, 91-96.	2.4	33
409	Histamine receptors are hot in immunopharmacology. <i>European Journal of Pharmacology</i> , 2006, 533, 69-76.	1.7	212
410	Regulation of T cells and cytokines by the interleukin-10 (IL-10)-family cytokines IL-19, IL-20, IL-22, IL-24 and IL-26. <i>European Journal of Immunology</i> , 2006, 36, 380-388.	1.6	129
411	T Regulatory Cells in Allergy. , 2006, 91, 159-173.		54
412	Mechanisms of Allergen-Specific Immunotherapy. , 2006, 91, 195-203.		30
413	The Role of Histamine in Regulation of Immune Responses. , 2006, 91, 174-187.		82
414	Are regulatory T cells the target of venom immunotherapy?. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2005, 5, 365-369.	1.1	27

#	ARTICLE	IF	CITATIONS
415	Role of bacillus Calmetteâ€“GuÃ©rin as an immunomodulator for the prevention and treatment of allergy and asthma. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2005, 5, 552-557.	1.1	11
416	T regulatory cells and allergy. <i>Microbes and Infection</i> , 2005, 7, 1049-1055.	1.0	28
417	Prevention of allergy by a recombinant multi-allergen vaccine with reduced IgE binding and preserved Tâ€„cell epitopes. <i>European Journal of Immunology</i> , 2005, 35, 3268-3276.	1.6	74
418	Targets in allergy-directed immunotherapy. <i>Expert Opinion on Therapeutic Targets</i> , 2005, 9, 217-224.	1.5	7
419	Apoptosis and Loss of Adhesion of Bronchial Epithelial Cells in Asthma. <i>International Archives of Allergy and Immunology</i> , 2005, 138, 142-150.	0.9	110
420	Impact of Sublingual Immunotherapy on Specific Antibody Levels in Asthmatic Children Allergic to House Dust Mites. <i>International Archives of Allergy and Immunology</i> , 2005, 136, 287-294.	0.9	131
421	Histamine in Allergic Inflammation and Immune Modulation. <i>International Archives of Allergy and Immunology</i> , 2005, 137, 82-92.	0.9	108
422	Cytokine and Antibody Responses in Birch-Pollen-Allergic Patients Treated with Genetically Modified Derivatives of the Major Birch Pollen Allergen Bet v 1. <i>International Archives of Allergy and Immunology</i> , 2005, 138, 59-66.	0.9	82
423	Future of allergen-specific immunotherapy. <i>Expert Opinion on Emerging Drugs</i> , 2005, 10, 1-4.	1.0	5
424	Advances in allergen-specific immunotherapy. <i>Expert Opinion on Biological Therapy</i> , 2005, 5, 537-544.	1.4	7
425	T Regulatory Cells in Allergen-Specific Immunotherapy. <i>International Reviews of Immunology</i> , 2005, 24, 533-548.	1.5	15
426	A major allergen gene-fusion protein for potential usage in allergen-specific immunotherapy. <i>Journal of Allergy and Clinical Immunology</i> , 2005, 115, 323-329.	1.5	95
427	T regulatory cells in allergy: Novel concepts in the pathogenesis, prevention, and treatment of allergic diseases. <i>Journal of Allergy and Clinical Immunology</i> , 2005, 116, 961-968.	1.5	295
428	T Regulatory Cells in Allergy and Health: A Question of Allergen Specificity and Balance. <i>International Archives of Allergy and Immunology</i> , 2004, 135, 73-82.	0.9	84
429	Apoptosis in tissue inflammation and allergic disease. <i>Current Opinion in Immunology</i> , 2004, 16, 717-723.	2.4	69
430	Immune Responses in Healthy and Allergic Individuals Are Characterized by a Fine Balance between Allergen-specific T Regulatory 1 and T Helper 2 Cells. <i>Journal of Experimental Medicine</i> , 2004, 199, 1567-1575.	4.2	960
431	Glucocorticoids upregulate FOXP3 expression and regulatory T cells in asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2004, 114, 1425-1433.	1.5	450
432	IL-10 and TGF-Î² cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. <i>European Journal of Immunology</i> , 2003, 33, 1205-1214.	1.6	836

#	ARTICLE	IF	CITATIONS
433	Inhibition of Tâ€„helperâ€„2-type responses, IgE production and eosinophilia by synthetic lipopeptides. <i>European Journal of Immunology</i> , 2003, 33, 2717-2726.	1.6	106
434	Human CD8 T cells of the peripheral blood contain a low CD8 expressing cytotoxic/effector subpopulation. <i>Immunology</i> , 2003, 108, 305-312.	2.0	44
435	Histamine in the immune regulation of allergic inflammation. <i>Journal of Allergy and Clinical Immunology</i> , 2003, 112, 15-22.	1.5	213
436	T helper (Th) 2 predominance in atopic diseases is due to preferential apoptosis of circulating memory/effector Th1 cells. <i>FASEB Journal</i> , 2003, 17, 1026-1035.	0.2	165
437	A Second Step of Chemotaxis After Transendothelial Migration: Keratinocytes Undergoing Apoptosis Release IFN-Î³-Inducible Protein 10, Monokine Induced by IFN-Î³, and IFN-Î³-Inducible I±-Chemoattractant for T Cell Chemotaxis Toward Epidermis in Atopic Dermatitis. <i>Journal of Immunology</i> , 2003, 171, 1078-1084.	0.4	118
438	IL-10 Controls <i>Aspergillus fumigatus</i> - and <i>Pseudomonas aeruginosa</i> -Specific T-Cell Response in Cystic Fibrosis. <i>Pediatric Research</i> , 2003, 53, 313-319.	1.1	28
439	T Cell Phenotype in Allergic Asthma and Atopic Dermatitis. <i>International Archives of Allergy and Immunology</i> , 2003, 131, 272-282.	0.9	35
440	IL-10 Controls <i>Aspergillus fumigatus</i> ??? and <i>Pseudomonas aeruginosa</i> ???Specific T-Cell Response in Cystic Fibrosis. <i>Pediatric Research</i> , 2003, 53, 313-319.	1.1	17
441	Key role of regulatory cytokines TGF-Î² and IL-10 as well as allergen-specific IgA and IgG4 in tolerance to mucosal antigens/allergens. <i>Journal of Allergy and Clinical Immunology</i> , 2002, 109, S45-S45.	1.5	0
442	T cells and eosinophils cooperate in the induction of bronchial epithelial cell apoptosis in asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2002, 109, 329-337.	1.5	176
443	Human NK1 and NK2 subsets determined by purification of IFN-Î³-secreting and IFN-Î³-nonsecreting NK cells. <i>European Journal of Immunology</i> , 2002, 32, 879.	1.6	81
444	The phosphatidylinositol phosphatase PTEN is under control of costimulation and regulates proliferation in human T cells. <i>European Journal of Immunology</i> , 2002, 32, 1196-1204.	1.6	25
445	T cells and effector mechanisms in the pathogenesis of atopic dermatitis. <i>Current Allergy and Asthma Reports</i> , 2002, 2, 1-3.	2.4	17
446	Immune regulation by histamine. <i>Current Opinion in Immunology</i> , 2002, 14, 735-740.	2.4	220
447	Targeting keratinocyte apoptosis in the treatment of atopic dermatitis and allergic contact dermatitis. <i>Journal of Allergy and Clinical Immunology</i> , 2001, 108, 839-846.	1.5	139
448	Bypassing IgE and targeting T cells for specific immunotherapy of allergy. <i>Trends in Immunology</i> , 2001, 22, 175-178.	2.9	52
449	New insights into the role of T cells in atopic dermatitis and allergic contact dermatitis. <i>Trends in Immunology</i> , 2001, 22, 530-532.	2.9	56
450	Mechanisms of interleukin-10-mediated immune suppression. <i>Immunology</i> , 2001, 103, 131-136.	2.0	329

#	ARTICLE	IF	CITATIONS
451	The Differential Fate of Cadherins during T-Cell-Induced Keratinocyte Apoptosis Leads to Spongiosis in Eczematous Dermatitis. <i>Journal of Investigative Dermatology</i> , 2001, 117, 927-934.	0.3	103
452	Role of IL-10 in allergen-specific immunotherapy and normal response to allergens. <i>Microbes and Infection</i> , 2001, 3, 891-898.	1.0	44
453	Histamine regulates T-cell and antibody responses by differential expression of H1 and H2 receptors. <i>Nature</i> , 2001, 413, 420-425.	13.7	537
454	Mechanism of IL-10-Induced T Cell Inactivation in Allergic Inflammation and Normal Response to Allergens. <i>International Archives of Allergy and Immunology</i> , 2001, 124, 180-182.	0.9	63
455	Role of Apoptosis in Atopic Dermatitis. <i>International Archives of Allergy and Immunology</i> , 2001, 124, 230-232.	0.9	17
456	Regulation of Allergic Inflammation by T Cells and Cytokines in Atopic Dermatitis. <i>International Archives of Allergy and Immunology</i> , 2001, 124, 296-298.	0.9	5
457	Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen, Bet v 1. <i>FASEB Journal</i> , 2001, 15, 2045-2047.	0.2	115
458	IL-10 directly acts on T cells by specifically altering the CD28 co-stimulation pathway. <i>European Journal of Immunology</i> , 2000, 30, 1683-1690.	1.6	207
459	Immune regulation in atopic dermatitis. <i>Current Opinion in Immunology</i> , 2000, 12, 641-646.	2.4	158
460	T Cell Epitope-Containing Hypoallergenic Recombinant Fragments of the Major Birch Pollen Allergen, Bet v 1, Induce Blocking Antibodies. <i>Journal of Immunology</i> , 2000, 165, 6653-6659.	0.4	110
461	A molecular basis for T cell suppression by IL-10: CD28-associated IL-10 receptor inhibits CD28 tyrosine phosphorylation and phosphatidylinositol 3-kinase binding. <i>FASEB Journal</i> , 2000, 14, 1666-1668.	0.2	151
462	Regulation of Specific Immune Responses by Chemical and Structural Modifications of Allergens. <i>International Archives of Allergy and Immunology</i> , 2000, 121, 261-269.	0.9	66
463	T cell-mediated Fas-induced keratinocyte apoptosis plays a key pathogenetic role in eczematous dermatitis. <i>Journal of Clinical Investigation</i> , 2000, 106, 25-35.	3.9	420
464	IL-10-induced anergy in peripheral T cell and reactivation by microenvironmental cytokines: two key steps in specific immunotherapy. <i>FASEB Journal</i> , 1999, 13, 603-609.	0.2	244
465	Regulation of Allergic Inflammation by Skin-Homing T Cells in Allergic Eczema. <i>International Archives of Allergy and Immunology</i> , 1999, 118, 140-144.	0.9	30
466	T Cells and T Cell-Derived Cytokines as Pathogenic Factors in the Nonallergic Form of Atopic Dermatitis. <i>Journal of Investigative Dermatology</i> , 1999, 113, 628-634.	0.3	165
467	Differential regulation of human T cell cytokine patterns and IgE and IgG4 responses by conformational antigen variants. <i>European Journal of Immunology</i> , 1998, 28, 914-925.	1.6	88
468	Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. <i>Journal of Allergy and Clinical Immunology</i> , 1998, 101, 747-754.	1.0	423

#	ARTICLE	IF	CITATIONS
469	Glucocorticoids inhibit human antigen-specific and enhance total IgE and IgG4 production due to differential effects on T and B cells in vitro. <i>European Journal of Immunology</i> , 1997, 27, 2351-2357.	1.6	50
470	Chemiluminescent and Enzyme-Linked Immuno Assays for Sensitive Detection of Human IFN- γ . <i>Journal of Immunoassay</i> , 1994, 15, 217-238.	0.3	31
471	The External Exposome and Allergies: From the Perspective of the Epithelial Barrier Hypothesis. <i>Frontiers in Allergy</i> , 0, 3, .	1.2	30